#### Intellia Therapeutics, Inc. Form 3 December 20, 2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB APPROVAL FORM 3 Washington, D.C. 20549 OMB Number:

#### **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Bell Graeme			<ol> <li>Date of Event Requiring Statement (Month/Day/Year)</li> </ol>	3. Issuer Name <b>and</b> Ticker or Trading Symbol Intellia Therapeutics, Inc. [NTLA]				
(Last)	(First)	(Middle)	12/12/2016	4. Relationship of Reporting Person(s) to Issuer		5. If Amendment, Date Original Filed(Month/Day/Year)		
C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130 (Street) CAMBRIDGE, MA 02139				(Checl Directo X Officer (give title belo	(Check all applicable) (Check all applicable) Director 10% Owner Officer Other (give title below) (specify below) EVP, Chief Financial Officer		<ul> <li>6. Individual or Joint/Group</li> <li>Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting</li> <li>Person</li> <li> Form filed by More than One</li> </ul>	
(City)	(State)	(Zip)	Table I -	Non-Deriva	tive Securitie	es Be	Reporting Person eneficially Owned	
1.Title of Secu (Instr. 4)	rity		2. Amount Beneficially (Instr. 4)	of Securities y Owned	Ownership	4. Na Owne (Instr	-	
Reminder: Report on a separate line for each class of securities beneficia owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displa currently valid OMB control number.				f	SEC 1473 (7-02)	)		

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	Derivative Security	2	

3235-0104

January 31,

2005

0.5

Expires:

response...

Estimated average burden hours per

or Indirec
(I)
(Instr. 5)

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Bell Graeme C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130 CAMBRIDGE, MA 02139	Â	Â	EVP, Chief Financial Officer	Â		
Signatures						
/s/ Nicole Heifner, 12/2 attorney-in-fact	20/2016					
**Signature of Reporting Person	Date					
Explanation of Responses:						

### No securities are beneficially owned

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

## Â

#### **Remarks:**

### No securities are beneficially owned.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.